Jul 1 |
ChromaDex to join Russell 2000 Index
|
Jul 1 |
ChromaDex to Join Russell 2000® Index
|
Jun 26 |
ChromaDex: Looking To Take The Big Step Into Pharma
|
Jun 24 |
Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)
|
Jun 15 |
Here's Why We Think ChromaDex Corporation's (NASDAQ:CDXC) CEO Compensation Looks Fair
|
Jun 13 |
ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)
|
Jun 10 |
ChromaDex (CDXC) Up as Ataxia Candidate Gets Orphan Drug Tag
|
Jun 7 |
ChromaDex shares jump 9% on FDA designations for NRC
|
Jun 7 |
ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)
|
Jun 4 |
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, June 11, 2024
|